1 / 8

Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management

Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management. NCI Workshop Bethesda, MD May 3 – 4, 2012. Challenges. Rapidly Changing Landscape Pace of technology development Pace of information generation (TCGA, 1000 Genomes)

josephdavis
Download Presentation

Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Next-Generation DNA Sequencing as a Tool for Clinical Decision-making in Cancer Patient Management NCI Workshop Bethesda, MD May 3 – 4, 2012

  2. Challenges • Rapidly Changing Landscape • Pace of technology development • Pace of information generation (TCGA, 1000 Genomes) • Need for larger, diverse research teams • Trial designs • Cost • Regulatory issues

  3. Technology • Genome sequencing has become faster, cheaper • Several platforms already in use • New platforms sequence “deeper”, faster • Produce copious amounts of data • Patients already having sequencing done; presenting data to their clinicians for interpretation and ACTION. • Data on what action is appropriate is sparse

  4. Data Analysis • High dimensional: more data than samples • Few experts: each experiment has “unique” modeling algorithm • Repeatability • Validation (samples, data) • Data integrity (quality assurance, control)

  5. Diagnostic Development: research test to clinical utility Necessary Assay Characteristics • Reproducible (intra and inter lab; ? Inter platform) • Clinically validated in more than one set of appropriate samples • Clinically useful • ?Predictive

  6. Goals • Bring together multidisciplinary experts to enhance communication • Define hurdles • Develop recommendations to overcome current obstacles

  7. Agenda/Outcome • Short talks with question period • Analytic issues • Data analysis/bioinformatics • Clinical/regulatory • Breakout sessions • Reporting session • Meeting report

  8. Meeting Planning: Thanks • Margo Cavenagh • FDA CDRH: • Elizabeth Mansfield • Association of Molecular Pathology • Jane Gibson, Mel Limson, Mary Williams • NCI • Jack R. Collins, Sean Davis, John Jessup, Lisa McShane, Paul Meltzer, Mei Polley, Mark Raffeld, JoyAnn Phillips Rohan, Robert Stephens, Liquiang Xi

More Related